Drug intelligence / Profile preview

BMS-986209

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986209 is an orally available small molecule drug that acts as a selective inhibitor of factor XIa, a key enzyme in the intrinsic pathway of blood coagulation. It is being developed by Bristol Myers Squibb for the prevention and treatment of thrombotic disorders. The drug's mechanism targets factor XIa to reduce thrombosis risk while potentially minimizing bleeding complications compared to conventional anticoagulants. As of late 2023, BMS-986209 has completed phase 1 clinical trials in healthy volunteers, with no further development reported at this time[1][3][5].

Targets

Factor XIa

Beyond the preview

Go deeper on BMS-986209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986209.

Explore the full profile